NEXTURNBIOSCIENCE Co., Ltd. (KOSDAQ:089140)
South Korea
· Delayed Price · Currency is KRW 2,770.00
+65.00 (2.40%)
Last updated: May 12, 2025
NEXTURNBIOSCIENCE Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 31,640 | 41,258 | 23,463 | 16,972 | 9,685 | Upgrade
|
| Revenue Growth (YoY) | -23.31% | 75.84% | 38.24% | 75.24% | -61.43% | Upgrade
|
| Cost of Revenue | 24,879 | 32,137 | 18,114 | 12,228 | 7,548 | Upgrade
|
| Gross Profit | 6,762 | 9,121 | 5,349 | 4,744 | 2,137 | Upgrade
|
| Selling, General & Admin | 5,331 | 5,358 | 6,219 | 5,242 | 2,180 | Upgrade
|
| Research & Development | 444.33 | 483.4 | 893.45 | 916.16 | 1,021 | Upgrade
|
| Other Operating Expenses | 489.47 | 504.47 | 506.17 | 221.07 | 146.33 | Upgrade
|
| Operating Expenses | 8,208 | 10,391 | 9,879 | 7,134 | 5,155 | Upgrade
|
| Operating Income | -1,446 | -1,271 | -4,529 | -2,390 | -3,018 | Upgrade
|
| Interest Expense | -5,465 | -4,076 | -5,667 | -2,416 | -1.04 | Upgrade
|
| Interest & Investment Income | 6,589 | 6,307 | 6,179 | 1,851 | 497.94 | Upgrade
|
| Currency Exchange Gain (Loss) | 961.52 | 430.1 | 189.89 | 1,249 | -1,643 | Upgrade
|
| Other Non Operating Income (Expenses) | 1,312 | -5,211 | 641.75 | 751.38 | 389.4 | Upgrade
|
| EBT Excluding Unusual Items | 1,953 | -3,820 | -3,186 | -953.76 | -3,774 | Upgrade
|
| Gain (Loss) on Sale of Investments | -15,419 | 21,292 | -3,815 | -3,067 | 343.42 | Upgrade
|
| Gain (Loss) on Sale of Assets | 50.88 | 57.76 | 2,351 | 23.71 | 0.95 | Upgrade
|
| Asset Writedown | - | -645 | - | - | - | Upgrade
|
| Other Unusual Items | -1,016 | 38.54 | 11.13 | - | - | Upgrade
|
| Pretax Income | -14,432 | 16,923 | -4,639 | -3,997 | -3,430 | Upgrade
|
| Income Tax Expense | -1,427 | 7,648 | 240.12 | 435.54 | -993.76 | Upgrade
|
| Earnings From Continuing Operations | -13,005 | 9,275 | -4,879 | -4,433 | -2,436 | Upgrade
|
| Earnings From Discontinued Operations | - | 406.33 | 190.43 | - | - | Upgrade
|
| Net Income | -13,005 | 9,681 | -4,688 | -4,433 | -2,436 | Upgrade
|
| Net Income to Common | -13,005 | 9,681 | -4,688 | -4,433 | -2,436 | Upgrade
|
| Shares Outstanding (Basic) | 11 | 9 | 7 | 6 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 10 | 7 | 6 | 6 | Upgrade
|
| Shares Change (YoY) | 8.38% | 48.59% | 5.86% | - | - | Upgrade
|
| EPS (Basic) | -1189.64 | 1086.74 | -690.64 | -691.28 | -379.94 | Upgrade
|
| EPS (Diluted) | -1190.00 | 885.38 | -690.95 | -691.28 | -380.00 | Upgrade
|
| Free Cash Flow | -1,788 | -3,047 | -1,407 | 3,197 | -979.05 | Upgrade
|
| Free Cash Flow Per Share | -163.53 | -302.11 | -207.29 | 498.56 | -152.68 | Upgrade
|
| Gross Margin | 21.37% | 22.11% | 22.80% | 27.95% | 22.07% | Upgrade
|
| Operating Margin | -4.57% | -3.08% | -19.30% | -14.08% | -31.16% | Upgrade
|
| Profit Margin | -41.10% | 23.46% | -19.98% | -26.12% | -25.15% | Upgrade
|
| Free Cash Flow Margin | -5.65% | -7.39% | -6.00% | 18.84% | -10.11% | Upgrade
|
| EBITDA | 567.07 | 731.84 | -2,721 | -1,338 | -2,503 | Upgrade
|
| EBITDA Margin | 1.79% | 1.77% | -11.60% | -7.89% | -25.85% | Upgrade
|
| D&A For EBITDA | 2,013 | 2,002 | 1,808 | 1,051 | 514.56 | Upgrade
|
| EBIT | -1,446 | -1,271 | -4,529 | -2,390 | -3,018 | Upgrade
|
| EBIT Margin | -4.57% | -3.08% | -19.30% | -14.08% | -31.16% | Upgrade
|
| Effective Tax Rate | - | 45.20% | - | - | - | Upgrade
|
| Advertising Expenses | 116.74 | 26 | 163.43 | 176.3 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.